Biosceptre (Aust) Pty Ltd.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Previously recorded as Biosceptre International Limited (to 2016)
14
Ending by 2030
Sep 2028
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Mar 8, 2027The maintenance fee for Anti P2X7 Receptor Antibodies and Fragments Thereof (US 9,127,059) comes due Mar 8, 2027. Unpaid by Sep 8, 2027, it lapses early.
- 1 fee due May 10, 2027The maintenance fee for Peptides for generating an antibody selectively binding to a non-ATP-binding P2X7 receptor but not to an ATP-binding P2X7 receptor (US 9,181,320) comes due May 10, 2027. Unpaid by Nov 10, 2027, it lapses early.
- 1 fee due Jul 28, 2027The maintenance fee for Combination therapy utilizing P2X7 peptides (US 10,543,262) comes due Jul 28, 2027. Unpaid by Jan 28, 2028, it lapses early.
- 1 fee due Sep 24, 2027The maintenance fee for Methods of treating cancer with a P2X7 peptide (US 10,597,451) comes due Sep 24, 2027. Unpaid by Mar 24, 2028, it lapses early.
- 1 fee due Nov 3, 2027The maintenance fee for Peptides for inducing antibodies to a non-functional P2X7 receptor (US 9,328,155) comes due Nov 3, 2027. Unpaid by May 3, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,658,385 | Purinergic (P2X) Receptors in Extra-Cellular Body Fluid In force · High confidence | In force | High confidence | |
| US 9,181,320 | Peptides for generating an antibody selectively binding to a non-ATP-binding P2X7 receptor but not to an ATP-binding P2X7 receptor In force · From the USPTO record | In force | From the USPTO record | |
| US 9,944,701 | Methods of treating cancer with antibodies that bind P2X7 receptors In force · From the USPTO record | In force | From the USPTO record | |
| US 10,597,451 | Methods of treating cancer with a P2X7 peptide In force · From the USPTO record | In force | From the USPTO record | |
| US 8,293,491 | Purinergic (P2X) Receptors in Extra-Cellular Body Fluid In force · High confidence | In force | High confidence | |
| US 8,440,186 | P2X7 epitopes In force · From the USPTO record | In force | From the USPTO record | |
| US 8,597,643 | Antibodies for binding to non-functional P2X7 receptors in trimeric form In force · From the USPTO record | In force | From the USPTO record | |
| US 9,328,155 | Peptides for inducing antibodies to a non-functional P2X7 receptor In force · From the USPTO record | In force | From the USPTO record | |
| US 10,238,716 | Anti- P2X7 Peptides and Epitopes In force · Medium confidence | In force | Medium confidence | |
| US 9,688,771 | Anti P2X7 receptor antibodies and fragments thereof In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 23: 8 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
7 pending · 1 no status recorded